



## NEWS RELEASE

**For Further Information Contact:**

Roy Wolvin  
Nymox Pharmaceutical Corporation  
1-800-93NYMOX  
[www.nymox.com](http://www.nymox.com)

**For Immediate Release:**

### **Nymox Pharmaceutical to Present at the 29th Annual Westergaard SmallCap Conference**

HASBROUCK HEIGHTS, NJ (November 3, 2006) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that Dr. Paul Averbach, CEO of Nymox Pharmaceutical, will present at the 29th Annual Westergaard SmallCap Conference on Monday, November 6, 2006. The conference is being held at the Waldorf Astoria in New York City and is being hosted by Paulson Investment Company and Dutton Associates.

Dr. Averbach will provide an overview of the Company's recent progress in drug development. The Company recently announced positive efficacy and safety results from its Phase 2 trial of NX-1207, its new drug for enlarged prostate (benign prostatic hyperplasia or BPH), a common affliction of older men. Forty-three clinical trial sites across the U.S. and 175 subjects participated in the double-blind, placebo controlled trial. Overall, patients treated with NX-1207 showed a significant improvement in BPH symptom score as compared to placebo and as compared to reported symptom score improvements for currently approved drugs for BPH. The results of the trial also demonstrated an excellent safety and side effect profile for NX-1207.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email:[info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*